SIGN receptors and the antiinflammatory activity of sialylated IgG Fcs

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1034526

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

IgG antibodies are a crucial component of the immune system, and significantly contribute to host protection against cancer and infectious diseases. Additionally, therapeutic IgG antibodies have been developed for treatment of cancer and inflammatory diseases. The studies proposed herein will elucidate one important aspect of how IgG antibodies act as anti-inflammatory agents, and may lead to the design of more effective IgG based therapies for the treatment of inflammatory diseases or cancer.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Autoimmunity

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibody engineering | antibody therapy | arthritis | glycosylation | lectins

Related Links